Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases

Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases

The JAK2 V617F somatic mutation is one of the most frequent markers of CHIP (clonal hematopoiesis of indeterminate potential). CHIP is characterized by the presence of a myeloid cells clone in peripheral blood in the absence of the sufficient reasons to diagnose the hematologic disease. The CHIP is...

Full description

Bibliographic Details
Main Authors:	I A Olkhovskiy, A S Gorbenko, M A Stolyar, D A Grischenko, O A Tkachenko, T L Martsinkevich
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2019-07-01
Series:	Терапевтический архив
Subjects:	atherosclerosis chd (coronary heart disease) somatic mutation jak2 v617f clonal hematopoiesis of indeterminate potential (chip) mpn (myeloproliferative neoplasms)
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/33576

Similar Items

JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women
by: I. A. Olkhovskiy, et al.
Published: (2019-09-01)

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
by: Florian Perner, et al.
Published: (2019-08-01)

Janus kinase V617F mutation detection in patients with myelofibrosis
by: Nikolova D, et al.
Published: (2019-08-01)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
by: Lasse Kjær
Published: (2020-07-01)

Evaluation of JAK2V617F Mutation Patients with Non-CML Myeloproliferative Neoplasms by ARMS-PCR
by: K Alimoghaddam, et al.
Published: (2008-09-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases—an updated systematic review
by: Nagendra Boopathy Senguttuvan, et al.
Published: (2021-07-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
by: Theodore P. Braun, et al.
Published: (2015-01-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
by: Kaveh Tari, et al.
Published: (2015-04-01)

Introducción del estudio molecular de la mutación JAK2V617F en neoplasias mieloproliferativas clásicas BCR-ABL negativas
by: Ana María Amor-Vigil, et al.

The Importance of Identification of M-BCRABL Oncogene and JAK2V617F Mutation in Myeloproliferative Neoplasms
by: Szántó Annamária, et al.
Published: (2014-04-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease
by: Yi-Chun Huang, et al.
Published: (2021-09-01)

PCR-HRM for Detecting JAK2V617F Gene Mutation: Is It a Sensitive Assay?
by: Mitra Rezaei, et al.
Published: (2020-04-01)

JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation
by: Čolović Milica, et al.
Published: (2010-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Thrombosis among 1537 patients with JAK2V617F‐mutated myeloproliferative neoplasms: Risk factors and development of a predictive model
by: Yuhui Zhang, et al.
Published: (2020-03-01)

Development of a highly sensitive method for detection of JAK2V617F
by: Gao Rufei, et al.
Published: (2011-10-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

Evaluation of the Effect of <italic>NQO1 C609T (rs1800566)</italic> Gene Variations in Philadelphia-negative Myeloproliferative Neoplasms in Turkish Population
by: Ayşegül Başak Akadam Teker, et al.
Published: (2020-01-01)

Meilensteine in der Verlaufskontrolle von Patienten mit JAK2 p.V617F positiver myeloproliferativer Neoplasie nach Stammzelltransplantation
by: Edelmann, Anja
Published: (2014)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
by: Gregor Hoermann, et al.
Published: (2020-08-01)

Rôle des cellules endothéliales avec mutation JAK2V617F et des polynucléaires neutrophiles dans la physiopathologie de la thrombose des néoplasies myéloprolifératives
by: Guy, Alexandre
Published: (2018)

Clinical meaning of JAK2 V617F mutation in chronic myeloproliferative disorders – the first experience
by: Joško Vučković, et al.
Published: (2006-10-01)

Rôle des cellules endothéliales JAK2V617F dans l’augmentation de l’angiogenèse des néoplasies myéloprolifératives.
by: Kilani, Badr
Published: (2015)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01)

SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms
by: Trifa Adrian P., et al.
Published: (2020-07-01)

Budd‐Chiari syndrome on background of JAK2V617F mutation with no hematologic abnormalities
by: Ammara Bint I Bilal, et al.
Published: (2021-09-01)

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
by: Min Hu, et al.
Published: (2019-02-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Cannot write session to /tmp/vufind_sessions/sess_rcmlp178e03o408a3aefpre8q2